Oncternal Should Be On Your Radar As Speculative Play Based On Recent Progress [Seeking Alpha]
Oncternal Therapeutics, Inc. (ONCT)
Last oncternal therapeutics, inc. earnings: 8/8 04:01 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
Oncternal Should Be On Your Radar As Speculative Play Based On Recent Progress Summary Oncternal opened enrollment for phase 1b expansion cohort dealing with the use of cirmtuzumab to treat patients with chronic lymphocytic leukemia and mantle cell lymphoma. Cirmtuzumab is ideal as a cancer drug because the targeting of ROR1 works out since healthy adult cells don't typically express this protein. TK216 is an inhibitor of a host of oncogenes that drives proteins for a variety of solid tumors, especially that of Ewing Sarcoma. A program is being developed to incorporate cirmtuzumab, which targets the ROR1 protein, into a CAR-T treatment that can potentially reduce/stop cancer relapse in patients. Oncternal Therapeutics ( ONCT Expanded Cohort Upon Positive Preliminary Findings A good thing about Oncternal is that the targeting of ROR1 is highly ideal. The reason why I make that claim is that it is a target that is uniquely expressed in cancer cells. It is not often expressed in healthy
Show less
Read more
Impact Snapshot
Event Time:
ONCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCT alerts
High impacting Oncternal Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ONCT
News
- Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer [Yahoo! Finance]Yahoo! Finance
- Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerGlobeNewswire
- Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Oncternal Therapeutics, Inc. (NASDAQ: ONCT) had its price target lowered by analysts at HC Wainwright from $30.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
ONCT
Earnings
- 3/7/24 - Miss
ONCT
Sec Filings
- 4/10/24 - Form 4
- 4/1/24 - Form 4
- 3/8/24 - Form S-3
- ONCT's page on the SEC website